Lukas biomedical Inc. (6814) Stock Statistics & Valuation Metrics
Total Valuation
Lukas biomedical Inc. has a market cap or net worth of TWD 749.55M. The enterprise value is ―.
- Market Cap
- TWD 749.55M
- Enterprise Value
- ―
Share Statistics
Lukas biomedical Inc. has 41,874,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 41,874,370
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Lukas biomedical Inc.’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is -20.30%.
- Return on Equity (ROE)
- -0.36
- Return on Assets (ROA)
- -0.20
- Return on Invested Capital (ROIC)
- -20.30%
- Return on Capital Employed (ROCE)
- -0.26
- Revenue Per Employee
- 2.06M
- Profits Per Employee
- -984.29K
- Employee Count
- 87
- Asset Turnover
- 0.42
- Inventory Turnover
- 2.37
Valuation Ratios
The current PE Ratio of Lukas biomedical Inc. is -7.95. Lukas biomedical Inc.’s PEG ratio is -2.89.
- PE Ratio
- -7.95
- PS Ratio
- 4.31
- PB Ratio
- 3.83
- Price to FCF
- -10.80
- Price to Operating Cash Flow
- -10.98
- PEG Ratio
- -2.89
Income Statement
In the last 12 months, Lukas biomedical Inc. had revenue of 179.49M and earned -85.63M in profits. Earnings per share was -2.04.
- Revenue
- 179.49M
- Gross Profit
- 95.69M
- Operating Income
- -81.16M
- Pretax Income
- -83.76M
- Net Income
- -85.63M
- EBITDA
- -56.12M
- Earnings Per Share (EPS)
- -2.04
Cash Flow
In the last 12 months, operating cash flow was -66.75M and capital expenditures -1.11M, giving a free cash flow of -67.87M billion.
- Operating Cash Flow
- -66.75M
- Free Cash Flow
- -67.87M
- Free Cash Flow per Share
- -1.62
Dividends & Yields
Lukas biomedical Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.21%
- Earnings Yield
- -12.49%
Stock Price Statistics
- Beta
- 0.03
- 52-Week Price Change
- -39.93%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 42.33
- Average Volume (3m)
- 18.02K
Financial Position
Lukas biomedical Inc. as a current ratio of 0.80, with Debt / Equity ratio of 64.96%
- Current Ratio
- 0.80
- Quick Ratio
- 0.50
- Debt to Market Cap
- 0.10
- Net Debt to EBITDA
- -2.16
- Interest Coverage Ratio
- -25.28
Taxes
In the past 12 months, Lukas biomedical Inc. has paid 1.87M in taxes.
- Income Tax
- 1.87M
- Effective Tax Rate
- -0.02
Enterprise Valuation
Lukas biomedical Inc. EV to EBITDA ratio is -15.34, with an EV/FCF ratio of -14.13.
- EV to Sales
- 5.64
- EV to EBITDA
- -15.34
- EV to Free Cash Flow
- -14.13
- EV to Operating Cash Flow
- -14.37
Balance Sheet
Lukas biomedical Inc. has TWD 26.81M in cash and marketable securities with TWD 248.75M in debt, giving a net cash position of -TWD 221.94M billion.
- Cash & Marketable Securities
- TWD 26.81M
- Total Debt
- TWD 248.75M
- Net Cash
- -TWD 221.94M
- Net Cash Per Share
- -TWD 5.30
- Tangible Book Value Per Share
- TWD 4.56
Margins
Gross margin is 52.90%, with operating margin of -51.26%, and net profit margin of -54.14%.
- Gross Margin
- 52.90%
- Operating Margin
- -51.26%
- Pretax Margin
- -53.04%
- Net Profit Margin
- -54.14%
- EBITDA Margin
- -36.76%
- EBIT Margin
- -51.26%
Analyst Forecast
The average price target for Lukas biomedical Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -5.72%
- EPS Growth Forecast
- 4.34%
